MRVL — Marvel Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- CA$4.70m
- CA$6.35m
Annual cashflow statement for Marvel Biosciences, fiscal year end - July 31st, CAD millions except per share, conversion factor applied.
2020 July 31st | 2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.011 | -3.04 | -2.55 | -2.29 | -1.65 |
| Depreciation | |||||
| Non-Cash Items | 0 | 1.78 | 0 | 0.08 | 0.286 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.001 | -0.115 | 0.36 | 0.879 | 0.185 |
| Change in Prepaid Expenses | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -0.009 | -1.37 | -2.19 | -1.33 | -1.18 |
| Other Investing Cash Flow Items | 0.01 | 0.382 | 0 | — | — |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Cash from Investing Activities | 0.01 | 0.382 | 0 | — | — |
| Financing Cash Flow Items | 0 | -0.023 | -0.026 | 0.026 | -0.031 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0 | 3.16 | 0.394 | 1.3 | 0.969 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 0.001 | 2.17 | -1.8 | -0.037 | -0.211 |